Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.

Lancet Respir Med · 2021 · PMC9765708 · PMID 33844995

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients with TMB higher than the median value of 8·3 mutations per Mb demonstrated an improved median overall survival than patients with TMB lower than the median value (30·9 months vs 14·9 months; p=0·06), although this difference did not reach statistical significance ( figure 4A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.